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Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting
single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly
decreases thrombin generation. Based on the results of phase III clinical trials, rivaroxaban, a direct Factor Xa
inhibitor, has been approved in many countries for the management of several thromboembolic disorders. Owing
to its predictable pharmacokinetic and pharmacodynamic characteristics, fixed-dose regimens are used without the
need for routine coagulation monitoring. In situations where assessment of rivaroxaban exposure may be helpful,
anti-Factor Xa chromogenic assays (in tandem with standard calibration curves generated with the use of
rivaroxaban calibrators and controls) could be used. It is important to note that test results will be affected by the
timing of blood sampling after rivaroxaban intake. In addition, the anti-Factor Xa method measures the drug
concentration and not the intensity of the drug’s anticoagulant activity, and a higher than expected rivaroxaban
plasma level does not necessarily indicate an increased risk of bleeding complications. Therefore, clinicians need
to consider test results in relation to the pharmacokinetics of rivaroxaban and other patient risk factors associated
with bleeding.
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Traditional anticoagulant agents such as vitamin K
antagonists (VKAs), unfractionated heparin (UFH), low
molecular weight heparins and fondaparinux have been
widely used in the prevention and treatment of
thromboembolic diseases. However, these agents are
associated with limitations, such as the need for regular
coagulation monitoring (VKAs and UFH) [1,2] or a par-
enteral route of administration (UFH, low molecular
weight heparin and fondaparinux) [2]. These limitations
have prompted the development of target-specific oral
anticoagulants that directly inhibit single enzymes in the
coagulation pathway, such as Factor Xa or thrombin.
Two direct Factor Xa inhibitors (rivaroxaban [Xarelto®,
Bayer Pharma AG and Janssen Pharmaceuticals, Inc.]
and apixaban [Eliquis®, Bristol-Myers Squibb and Pfizer
EEIG]) and a direct thrombin inhibitor (dabigatran
etexilate [Pradaxa®, Boehringer Ingelheim International* Correspondence: meyermichel.samama@biomnis.com
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reproduction in any medium, provided the orGmbH]) are approved in many countries for the preven-
tion of venous thromboembolism (VTE) after elective hip
or knee replacement surgery in adults, and in the European
Union (EU) and North America for the prevention of
stroke and systemic embolism in adult patients with non-
valvular atrial fibrillation [3-8]. In addition, rivaroxaban is
also approved in the EU and North America for the treat-
ment of deep vein thrombosis (DVT) and pulmonary
embolism, and prevention of recurrent DVT and pulmon-
ary embolism in adults, and is now approved in the EU, in
combination with antiplatelet agents, for the prevention of
atherothrombotic events in adults who have acute coro-
nary syndromes and elevated cardiac biomarkers [3,4,9].
The mechanisms of action of anticoagulant agents
have an important role in the prolongation of clotting
time in tests such as the prothrombin time (PT) test.
VKAs interfere with the γcarboxylation of glutamate
residues in Factors II, VII, IX and X, with the result that
the coagulant activity of these factors is diminished.
Direct Factor Xa inhibitors limit thrombogenesis via
selective inhibition of Factor Xa without requiring cofac-
tors such as antithrombin [10]. Direct thrombin inhibitors
target thrombin and, likewise, do not require cofactorsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agents have predictable, dose-dependent anticoagulant
effects [12]. Rivaroxaban inhibits free Factor Xa and pro-
thrombinase activity as well as clot-bound Factor Xa, thus
effectively blocking thrombin generation [13]. Inhibition
of Factor Xa activity by rivaroxaban is closely correlated to
its plasma concentration. Anti-Factor Xa activity can be
measured to indicate rivaroxaban exposure.
As with apixaban and dabigatran, rivaroxaban does
not require routine coagulation monitoring or dose
titration (unlike VKAs and UFH). However, a reliable
laboratory assay that could measure exposure to riva-
roxaban may be necessary or helpful in certain clinical
circumstances (e.g. prior to urgent surgery, for peri-
operative management of those receiving rivaroxaban,
for patients with thromboembolic or bleeding events, or
for suspected overdose). Because rivaroxaban and other
target-specific oral anticoagulants have different mecha-
nisms of action from traditional anticoagulant agents,
laboratory tests used for these traditional agents (such as
PT/international normalised ratio [INR] or activated
partial thromboplastin time) are not suitable for target-
specific oral anticoagulants [14]. This article will sum-
marise the pharmacokinetics and pharmacodynamics of
rivaroxaban and provide information and guidance on
laboratory tests that can be used for the measurement of
rivaroxaban in clinical practice.Pharmacokinetics and pharmacodynamics of
rivaroxaban
The oral bioavailability of rivaroxaban is 80–100% for
the 10 mg dose, irrespective of food intake [3,15]. Under
fed conditions, rivaroxaban 10 mg, 15 mg and 20 mg
tablets demonstrate dose-proportional bioavailability. In
a fasted state, rivaroxaban pharmacokinetics are appro-
ximately linear up to about 15 mg once daily, and oral
bioavailability is reduced to 66% after a 20 mg tablet; at
higher doses, bioavailability decreases as a result of poor
solubility [3,16]. Food does not affect the area under the
concentration–time curve or maximum plasma concen-
tration (Cmax) of the 10 mg dose [3]. The administered
oral dose of rivaroxaban is absorbed rapidly, with Cmax
occurring 2–4 hours after tablet intake [15].Table 1 Summary of pharmacokinetic characteristics of rivaro
Parameter
2.5 mg bid* 2.5 mg bid# 5 mg
AUC (μg.h/l) 300 328 464
Cmax (μg/l) 53 40 86
Ctrough (μg/l) 8 14 11
*Data are mean values from an analysis of the ODIXa-HIP2 study [17]. #Data are me
patients aged <50 years) [18]. ‡Data are mean values from an analysis of the ODIXa
Abbreviations: AUC area under the concentration–time curve, bid twice daily, Cmax mAt total daily oral doses of rivaroxaban of 5–60 mg,
Cmax ranges (mean values) from 40 μg/l to 400 μg/l, and
minimum plasma concentration (Ctrough) (mean values)
from 8 μg/l to 160 μg/l (data derived from phase II stu-
dies of rivaroxaban in patients undergoing hip replace-
ment surgery, patients with DVT or patients with acute
coronary syndrome; Table 1) [17-19].
No relevant accumulation occurs beyond steady state
in healthy individuals [20]. Elimination of rivaroxaban
from plasma occurs with a terminal half-life of 5–9 hours
in young individuals [3,20] and 11–13 hours in the
elderly [3,21]. Rivaroxaban has a dual mode of elimina-
tion. Of the administered dose, approximately two-thirds
undergoes metabolic degradation, half of which is elimi-
nated renally and the other half by the hepatobiliary
route. The final one-third of the administered dose
undergoes direct renal excretion as unchanged active
substance in the urine, mainly via active renal secretion.
Rivaroxaban has no major or active circulating metabo-
lites [3,22].
In phase I studies in healthy subjects [15,20,23] and in
phase II studies of patients undergoing major orthopaedic
surgery [17] or those with acute coronary syndrome [18],
rivaroxaban was found to have predictable, dose-
dependent pharmacokinetics. In addition, population
modelling suggests that pharmacokinetic parameters are
generally similar between different patient groups (i.e.
VTE prevention and treatment of acute DVT) [19].
Influence on coagulation assays
Prothrombin time
Rivaroxaban prolongs PT (measured in seconds or PT
ratio) in a linear and concentration-dependent manner
when using reagents sensitive to rivaroxaban, such as
Neoplastin Plus® (Diagnostica Stago, Asnières-sur-Seine,
France) or HemosIL RecombiPlasTin 2G (Instrumenta-
tion Laboratory, Bedford, MA, USA). However, results
vary according to the thromboplastin reagent used, as
shown by in vitro [13,24-26] and ex vivo studies in
patients undergoing hip or knee replacement surgery
(total daily doses of 5–60 mg) [17]. The concentration of
rivaroxaban required to double PT in human plasma
using Neoplastin Plus is 301 μg/l [13]. In contrast, the
concentration of rivaroxaban required to double PT inxaban at steady state based on phase II data
Rivaroxaban dose




dian values from an analysis of the ATLAS ACS TIMI 46 study (subset of
-DVT study [19].
aximum plasma concentration, Ctrough minimum plasma concentration.
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Diagnostics, Marburg, Germany) is 700 μg/l [24]. Neo-
plastin Plus can be used in a dilute PT test, which is more
sensitive than the PT test [24]. As with the PT test,
rivaroxaban results in a linear concentration-dependent
prolongation of dilute PT, with varying gradients of the
concentration–effect relationships for different thrombo-
plastin reagents, as shown by an in vitro study [24].
Other coagulation assays
Rivaroxaban prolongs clotting times concentration-
dependently in the activated partial thromboplastin time
[24], HepTest (Sekisui Diagnostics, Stamford, CT, USA
[27]) [15,20] and prothrombinase-induced clotting time
(PiCT) test [24,26,28]. However, for the HepTest and
PiCT test, there is a paradoxical shortening of clotting
time at low rivaroxaban concentrations when bovine
Factor Xa is used [24]. This effect is not seen with a
shorter or no incubation period, when antithrombin-
depleted (immunodeficient) plasma (instead of platelet-
poor plasma) is used [24,28], or when human Factor Xa is
used (in the PiCT test only) [28]. Rivaroxaban also affects
thrombin generation parameters (prolonging lag time and
time to peak of thrombin generation) and decreases peak
thrombin generation and endogenous thrombin potential
[24,29]. There is a more pronounced effect on the initi-
ation and propagation phases of thrombin generation than
on the decay phase [30]. However, thrombin generation
tests are not available in many clinical laboratories.
Inhibition of Factor Xa activity
Inhibition of Factor Xa and plasma rivaroxaban levels
are closely correlated [20]. Therefore, assays (particularly
chromogenic assays) that measure inhibition of Factor
Xa activity can quantify rivaroxaban plasma concentrations
[25,26,31-33]. These types of assay are able to measure a
wide range of rivaroxaban concentrations (e.g. 20–500 μg/l)
by use of a reference calibration curve for rivaroxaban
spiked in plasma [31]. Standardisation of these assays to
measure rivaroxaban involves the use of rivaroxaban cali-
brators and controls [33], and standardised assay kits are
now commercially available for clinical use (e.g. BIOPHEN
Factor X Chromogenic [Aniara, West Chester, OH, USA],
STA® Liquid Anti-Xa and STA® rivaroxaban calibrator and
control [Diagnostica Stago], Technochrom anti-Xa and
Technoview rivaroxaban calibrator and control [Techno-
clone GmbH, Vienna, Austria]).
Is prothrombin time suitable for measuring
rivaroxaban?
The variability in responses between thromboplastin
reagents used in the PT test is too large when the results
are expressed in seconds for samples containing the same
concentrations of rivaroxaban [24,34]. This variation iscaused by different sensitivities of the reagents to rivaro-
xaban [34], possibly caused by interactions between Factor
Xa inhibitors and phospholipids in thromboplastin
reagents [35]. This variability is not corrected by con-
version of PT to INR values [24]. The INR has been
developed specifically for monitoring anticoagulation with
VKAs [1] and, therefore, should not be used for rivaro-
xaban. Moreover, conversion of PT to INR values can
increase the variability [36].
Normal PT can indicate intact haemostatic function
[37]. An in vitro study showed that reduction of the vari-
ability in PT results across thromboplastin reagents by
use of an international sensitivity index valid for rivaro-
xaban is feasible [38]. In addition, a modified PT test
could be potentially useful [24]. Recently, a study
assessing rivaroxaban effect with Simplastin® Excel S
reagent (Tcoag Ireland, County Wicklow, Ireland) sug-
gested that it might have a similar effect to VKAs [39].
Results were reported in a field trial of 18 centres that
compared PT results from different laboratories using
different local reagents versus one central reagent and
local instruments. This trial reported inter-laboratory vari-
ation in mean PT values that was significantly reduced by
use of a centrally provided PT reagent (STA® Néoplastine
CI Plus [Diagnostica Stago]) and when results were
expressed as rivaroxaban concentrations (μg/l) [40]. This
method may be sensitive enough to measure peak rivaro-
xaban plasma concentrations that would occur after
currently approved therapeutic doses, i.e. provide a quali-
tative confirmation of the presence of rivaroxaban [37].
However, it lacks precision, particularly at low rivaroxaban
concentrations and is, therefore, not suitable for measu-
ring rivaroxaban levels in blood samples taken near the
time of Ctrough [37]. In addition, specific calibrators for use
with the PT test are not commercially available.
The effect of rivaroxaban (as with other target-specific
oral anticoagulants) on PT is short-lived (e.g. minimal
effect at 24 hours post-dosing [3]) and changes over
time, whereas the effects of VKAs on PT last for several
days [1,20,21]. In addition, the PT test, like other global
clotting assays, is not specific for Factor Xa and can be
influenced by many disease conditions, such as liver
disease, some types of cancer and Hodgkin’s disease
[41-43].
Are anti-Factor Xa chromogenic assays the
preferred method for measuring rivaroxaban?
Anti-Factor Xa chromogenic assays can accurately mea-
sure a wide range of rivaroxaban concentrations in
plasma – i.e. give a quantitative measure of the rivaro-
xaban level – provided that a standard calibration curve
is generated with rivaroxaban calibrators and controls
[33,44,45]. A field trial of 23 centres has shown that
anti-Factor Xa chromogenic assays, in conjunction with
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rivaroxaban concentrations in plasma in the range of
20–660 μg/l [33]. Furthermore, the mean rivaroxaban
concentrations measured were in agreement with the
expected values, even at the low rivaroxaban concentra-
tion when a modified STA® Rotachrom® test (Diagnostica
Stago) set-up was used. In this test, plasma samples were
diluted to a ratio of 1:4 in Owren–Koller assay buffer to en-
able measurement of rivaroxaban concentrations >100 μg/l.
Moreover, there was less variation among the different
laboratories when using the centrally provided reagent
compared with using local anti-Factor Xa reagents,
particularly for the lowest rivaroxaban plasma concentra-
tion. The coefficients of variation at 20 μg/l reached 37.0%
with local methods, compared with 19.1% with the
centrally provided reagent; 13.7% versus 10.9% at 199 μg/l
actual rivaroxaban value; and 14.1% versus 10.0% at
662 μg/l actual rivaroxaban value (1:3 diluted plasma). In
addition, a Swiss study across nine laboratories showed
that inter-laboratory precision of the chromogenic anti-
Factor Xa assay, Biophen Heparin 6 (Hyphen Biomed,
Neuilly-sur-Oise, France), was satisfactory, with the coeffi-
cient of variation in the range of 2.6–10.5% [45].
Another study measured rivaroxaban in ex vivo blood
samples from patients who received rivaroxaban 10 mg
once daily for VTE prevention after hip or knee replace-
ment surgery [44]. With the use of rivaroxaban calibra-
tors and controls (set to enable measurement of plasma
rivaroxaban ≥10 μg/l) in this study, three chromogenic
anti-Factor Xa methods were evaluated: one with the
addition of exogenous antithrombin (Technochrom®
anti-Xa [AT+] [Technoclone, Vienna, Austria]) and two
without the addition of antithrombin (COAMATIC®
Heparin [Chromogenix, Milan, Italy]; and Technochrom®
anti-Xa, [Technoclone]). All of the assays showed a linear
relationship between the optimal density of the chromo-
genic assays and rivaroxaban concentrations validated by
high-performance liquid chromatography coupled with
tandem mass spectrometry. However, the method in
which antithrombin was added detected falsely highTable 2 Rivaroxaban plasma concentrations after therapeutic
Dose Clinical setting
2.5 mg bid Acute coronary syndrome
10 mg od VTE prevention after total hip replacement
15 mg od Stroke prevention in patients with AF (CrCl ≤50
20 mg od DVT treatment (continued treatment)
20 mg od Stroke prevention in patients with AF (CrCl >50
*Estimated parameters at steady state – median values (5th–95th percentile range)
percentile range) in patients undergoing hip replacement surgery [46]. ‡Estimated p
stroke prevention in patients with AF (Bayer HealthCare Pharmaceuticals and Jansse
state – geometric means (5th–95th percentile range) in phase II studies in the acute
Abbreviations: AF atrial fibrillation, bid: twice daily, Cmax maximum plasma concentr
DVT deep vein thrombosis, od once daily, VTE venous thromboembolism.rivaroxaban levels [44]. These findings support the suit-
ability of anti-Factor Xa assays (without the addition of
antithrombin) in measuring rivaroxaban concentrations.
Although anti-Factor Xa chromogenic assays differ in
their sensitivity to rivaroxaban, mathematical modelling
could decrease the variation between assays [32]. Anti-
Factor Xa chromogenic assay kits specifically developed
for rivaroxaban calibrators and controls are now commer-
cially available for clinical use.
Interpretation of measured plasma levels
An understanding of expected rivaroxaban plasma con-
centrations after therapeutic doses is important for the
interpretation of measured results. The plasma levels of
rivaroxaban in phase II studies are shown in Table 2
[18,19,46].
In addition, data show that there is some inter-
individual variability in plasma rivaroxaban concentra-
tions, but the clinical relevance of this variation has not
been determined. In healthy individuals, approximate
geometric coefficients of variation for Cmax are 16% after
a 10 mg dose, 36% after a 20 mg dose [15] and 19% after
a 20 mg twice-daily dose [20]. However, after hip repla-
cement surgery, the geometric coefficients of variation
of rivaroxaban at total daily doses of 5–20 mg are higher
than in healthy individuals and in the range of 60–93%
for Ctrough and 47–74% for Cmax [17].
Accumulating data indicate that anti-Factor Xa chromo-
genic assays (with use of rivaroxaban calibrators and
controls) are able to measure a wide range of rivaroxaban
concentrations encompassing the entire range after thera-
peutic dosing [1,2,24]. The timing of blood sampling after
tablet intake is important because levels of rivaroxaban
change markedly over time owing to the pharmacokinetics
of the drug (e.g. levels of rivaroxaban will differ greatly
2–4 hours versus 24 hours after dosing).
Conclusions
Unlike VKAs, the target-specific oral anticoagulants (such
as rivaroxaban, dabigatran, apixaban and edoxaban) aredoses based on phase II data and simulated virtual data
Ctrough (μg/l) Cmax (μg/l)
16 (6–34)* 44 (28–66)*
9 (1–38)# 125 (91–196)#
ml/min) 57 (18–136)‡ 229 (178–313)‡
26 (6–87)§ 270 (189–419)§
ml/min) 44 (12–137)‡ 249 (184–343)‡
[18]. #Estimated parameters at steady state – median values (5th–95th
arameters at steady state – geometric means (5th–95th percentile range) in
n Research & Development, LLC: data on file). §Estimated parameters at steady
treatment of DVT [19].
ation, CrCl creatinine clearance, Ctrough minimum plasma concentration,
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the need for routine coagulation monitoring [47]. The
concentration of target-specific oral anticoagulants may
potentially need to be measured in certain clinical situa-
tions [48], such as before urgent surgery, perioperative
management, thromboembolic or bleeding events, or in
cases of suspected overdose. The conventional PT/INR
method has some important limitations. For measuring
apixaban, anti-Factor Xa chromogenic assays are prefera-
ble to the PT test because they yield more accurate results
[25]. Similarly, accumulating data indicate that the anti-
Factor Xa chromogenic assay is the most suitable assay for
the quantitative assessment of rivaroxaban, provided
rivaroxaban calibrators and controls are used, and results
are expressed as rivaroxaban concentration (μg/l) [33]. If
this method is not available or in an emergency situation,
such as before urgent surgery, the PT assay (expressed in
seconds) using a thromboplastin reagent sensitive to
rivaroxaban may be useful to indicate whether the anti-
coagulant effect of rivaroxaban is present [3], provided
that the patient's baseline PT is not abnormal. However,
interpretation of the results should take into account the
pharmacokinetic characteristics of rivaroxaban. A PT
reagent has recently been found to have particularly high
sensitivity to the effects of rivaroxaban, but no explanation
has been proposed [39]. A point-of-care assay has been
studied for the qualitative assessment of rivaroxaban in
urine samples [49], which may be potentially useful in
investigating treatment compliance, for example. How-
ever, this method needs further validation if it is to be
used in clinical practice.
Practical considerations for the quantitative measure-
ment of rivaroxaban using anti-Factor Xa chromogenic as-
says include the timing of blood sampling, interpretation
of test results and standardisation of the assays. The tim-
ing of blood sampling in relation to the pharmacokinetic
characteristics of rivaroxaban is important because it will
directly influence the test results; for example, plasma
levels of rivaroxaban will be high in the period 2–4 hours
after drug administration compared with 12–24 hours
after dosing. Therefore, an understanding of the expected
time to Cmax and Ctrough of rivaroxaban is important when
interpreting test results. Another practical consideration is
the interpretation of test results and potential clinical
implications. It is important to note that the anti-Factor
Xa method measures the drug concentration (quantitative
assessment) and not the intensity of the drug’s anticoa-
gulant activity (qualitative assessment) [24], whereas
coagulation assays used for monitoring the traditional
anticoagulants, VKAs and UFH, indicate the intensity of
anticoagulation [1,2]. In addition, a higher than expected
plasma level does not necessarily indicate an increased
risk of bleeding complications but could signal a need for
closer surveillance for risk of bleeding.Standardised anti-Factor Xa chromogenic assays with
rivaroxaban calibrators and controls (e.g. BIOPHEN
Factor X Chromogenic [Aniara], STA® Liquid anti-Xa
and STA® rivaroxaban calibrator and control [Diagnos-
tica Stago], Technochrom anti-Xa and Technoview riva-
roxaban calibrator and control [Technoclone]) are now
commercially available for clinical use. These assays
differ from the INR test and other clotting tests that
have been used to monitor traditional anticoagulant
agents in that the results are expressed as rivaroxaban
concentrations (μg/l).
The perioperative management of patients receiving
anticoagulants is an important issue, although guidelines
on this are scarce. The principles of when to interrupt
and resume rivaroxaban are based on the relatively short
half-life, rapid onset of action and dual route of elimi-
nation of rivaroxaban [50,51]. The current consensus is
that the last dose of rivaroxaban should be taken not less
than 24 hours before elective surgery [52], and the
manufacturer recommends resumption of rivaroxaban
6–10 hours after surgery, provided haemostasis has been
established [3].
Based on the consistent efficacy and safety profiles
demonstrated in the large-scale phase III clinical trial
programme, fixed-dose regimens of rivaroxaban have
been approved for clinical use in several indications.
Routine measurement of rivaroxaban plasma levels or its
pharmacodynamic effects is not required or recommen-
ded. Clinicians should adhere to the regulatory recom-
mendations or the label, particularly in patients or
clinical situations associated with an increased risk of
bleeding. At present, physicians have many questions on
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anticoagulants in clinical practice [53], and detailed
guidelines are lacking. For example, there is concern
among clinicians about switching between anticoagu-
lants and reversing anticoagulant effects; therefore, more
recommendations are needed, although the respective
labels of the newer agents provide some guidance on
these issues [3-8]. To conclude, the choice of laboratory
test for rivaroxaban will depend on the clinical situation:
if a qualitative assessment of the presence of rivaroxaban
in the blood is needed, the PT test is suitable provided
that a rivaroxaban-sensitive reagent is used, whereas if a
quantitative measurement of plasma rivaroxaban is
required, an anti-Factor Xa chromogenic assay in
tandem with rivaroxaban calibrators and controls with
results expressed as rivaroxaban concentration (μg/l) can
provide accurate results (Table 3). Whichever test is used,
interpretation of results must take into account the timing
of blood sampling (making reference to the pharmacoki-
netics of rivaroxaban) and differences in the functionality
of the assays (qualitative versus quantitative).
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